Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Border's Unused Idle and Lying Dormant Inventory Transfer Act or the BUILD IT Act This bill requires the federal government to transfer, upon request, materials associated with the construction of a barrier along the U.S.-Mexico border to the governments of the states along that border (i.e., Arizona, California, New Mexico, and Texas). The transferred materials must be used to construct a barrier along the U.S.-Mexico border.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2022 · fourth_quarter · Health Issues
HR 2617, the Consolidated Appropriations Act 2023; , HR 4385 / S 3080, the Cancer Drug Parity Act; HR 5030 / S 2706, the Diverse Trials Act; HR 7630 / 4120, Childhood Cancer STAR Reauthorization Act; HR 5416, the Give Kids a Chance Act; HR 6584, the DEPICT Act; HR 7512, the Protecting Patients from Deceptive Health Plans Act; HR 7667, the Food and Drug Amendments Act; specifically Title V; HR 8845, the NIH Clinical Trial Diversity Act; HR 8324, the Health Share Transparency Act; S 4185, the RARE Act; S 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; S 4294, Pharmacy Benefit Manager Transparency Act of 2022; FDA regulations regarding sites of delivery for clinical trial services; federal regulation of Short Term Limited Duration Insurance and other non-ACA compliant insurance plans; implementation of the No Surprises Act (enacted in the 116th Congress); Consumer Assistance Programs; 2024 Notice of Benefit and Payment Parameters regulation
Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Health Issues
HR 5776, the Build Back Better Act; HR 4385 / S 3080, the Cancer Drug Parity Act; HR 5030 / S 2706, the Diverse Trials Act; HR 7630 / 4120, Childhood Cancer STAR Reauthorization Act; HR 5416, the Give Kids a Chance Act; HR 6584, the DEPICT Act; HR 7512, the Protecting Patients from Deceptive Health Plans Act; HR 7667, the Food and Drug Amendments Act; specifically Title V; HR 8845, the NIH Clinical Trial Diversity Act; HR 8324, the Health Share Transparency Act; S 4185, the RARE Act; S 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; S 4294, Pharmacy Benefit Manager Transparency Act of 2022; HR 6833, the FY2023 Continuing Appropriations and Ukraine Supplemental Appropriations Act, specifically provisions related to FDA user fees; FDA regulations regarding sites of delivery for clinical trial services; federal regulation of Short Term Limited Duration Insurance and other non-ACA compliant insurance plans; implementation of the No Surprises Act (enacted in the 116th Congress); Consumer Assistance Programs; 2024 Notice of Benefit and Payment Parameters regulation
Client expense: $120,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · second_quarter · Health Issues
HR 5776, the Build Back Better Act; HR 4385 / S 3080, the Cancer Drug Parity Act; HR 5030 / S 2706, the Diverse Trials Act; HR 7630 / 4120, Childhood Cancer STAR Reauthorization Act; HR 5416, the Give Kids a Chance Act; HR 6584, the DEPICT Act; HR 7512, the Protecting Patients from Deceptive Health Plans Act; HR 7667, the Food and Drug Amendments Act; specifically Title V; HR 8845, the NIH Clinical Trial Diversity Act; HR 8324, the Health Share Transparency Act; S 4185, the RARE Act; S 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; S 4294, Pharmacy Benefit Manager Transparency Act of 2022; FDA regulations regarding sites of delivery for clinical trial services; federal regulation of Short Term Limited Duration Insurance and other non-ACA compliant insurance plans; implementation of the No Surprises Act (enacted in the 116th Congress); Consumer Assistance Programs;
Client expense: $170,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Republican |
| MT |
| Ted Cruz | Republican | TX |